{
    "nctId": "NCT02692651",
    "officialTitle": "A Comparison of Fidaxomicin and Oral Vancomycin for the Treatment of Clostridium Difficile Infection (CDI) in Hospitalized Patients Receiving Concomitant Antibiotics for the Treatment of Concurrent Systemic Infections",
    "inclusionCriteria": "* Patients 18 years of age or older with \\>3 unformed stools/24 hours with positive stool test for C. difficile.\n* Patients receiving \u2265 1 high or medium risk antibiotic for treatment of an infection other than CDI, for an anticipated duration of \u2265 5 days from the time of enrollment.\n\n  * High risk: carbapenems, 2nd-4th generation cephalosporins, fluoroquinolones, clindamycin, and beta-lactam/beta-lactamase inhibitor combinations\n  * Medium risk: 1st generation cephalosporin, macrolides\\*, and aztreonam\n\n    * \\*The macrolide would be considered to be low risk if patients are receiving intermittent macrolides for prophylaxis only and not for treatment of an acute infection\n* Must have minimum age of 18 Years",
    "exclusionCriteria": "* Patients with severe-complicated disease that would compromise oral therapy (hypotenstion or shock, ileus or bowel obstruction, megacolon).\n* Patients with an allergy to oral vancomycin or fidaxomicin.\n* Patients anticipated to receive metronidazole after enrollment.\n* Patients who already received oral vancomycin or metronidazole (either oral or intravenous) for \\> 24 hours within the preceding 72 hours at the time of enrollment.\n* Patients anticipated to receive adjunctive C. difficile therapy (rifaxamin, nitazoxanide, tigecycline) after enrollment.\n* Patients who are on laxatives before they are enrolled into the study, such as lactulose, if:\n\n  * Patients have had a recent dose adjustment;\n  * Baseline number of bowel movement while on laxatives is unknown.\n  * Number of bowel movements and/or consistency has not changed from baseline.\n* Patients who have had colostomy or ileostomy\n* Patients who will have colostomy or ileostomy after enrollment and before study ends\n* Patients who are or will be on long-term (\\>12 weeks) medium or high-risk antibiotics prophylaxis after enrollment"
}